Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast Cancer

Release Date: May 30, 2017
Expiration Date: May 30, 2018
Media: Internet - based

 

Activity Overview

Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast Cancer is a continuing medical education (CME)-certified activity based on a symposium of the same name held adjunct to the 34th Annual Miami Breast Cancer Conference®, a PER® Legacy International Conference.

Optimization of outcomes for patients with estrogen receptor‒positive (ER+), human epidermal growth factor 2‒negative (HER2-), metastatic breast cancer continues to be a significant unmet clinical need. Although endocrine therapy has been the cornerstone of therapy for patients with ER+ breast cancer for decades, the emergence of resistance to endocrine therapy is quite common. New treatment options have emerged over the past 5 years, and the therapeutic landscape continues to evolve at a rapid pace. Clinical investigation is yielding exciting data regarding new therapies and combinations, such as those involving CDK4/6 inhibitors. At the same time, the volume of information adds markedly to the complexity of the treatment decision-making process.

This activity incorporates the perspectives of internationally recognized experts in breast cancer therapy who will discuss the evolving role of CDK4/6 inhibitors in the management of these patients. Essential topics will be addressed in this activity, including:

  • Current perspectives on the management of patients with ER+, HER2- metastatic breast cancer
  • Role of CDK4/6 in cell cycle progression regulation and tumor pathogenesis
  • Rationale for pursuing CDK as a target for drug development
  • Development of individualized treatment algorithms that reflect an understanding of the latest clinical data pertaining to CDK4/6 inhibitors
    • Recognition and management of CDK4/6 inhibitor‒related adverse events
    • Tailoring treatment to specific patient populations
    • Points of ongoing clinical investigation
  • Future indications and combination strategies for CDK4/6 inhibitors

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

CME/CE Activity Table of Contents

  • Historical Perspectives: Clinically Unmet Needs in the Management of ER+, Metastatic Breast Cancer
    Commentary featuring Joyce O’Shaughnessy, MD
  • Assessing Cyclin-Dependent Kinases and Their Role in Breast Cancer Pathogenesis
    Commentary featuring Kimberly Blackwell, MD
  • Key Findings From Clinical Trials Evaluating CDK4/6 Inhibitors in Metastatic Breast Cancer
    Commentary featuring Hope S. Rugo, MD
  • CDK4/6 Inhibitors: Clinical Considerations for Toxicity Management of CDK4/6 Inhibitor Therapies
    Commentary featuring Sara Hurvitz, MD

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast

Learning Objectives

Upon completion of this activity, participants should be better prepared to:

  • Describe the role of CDK 4/6 in cell cycle regulation and the mechanistic rationale for development of CDK4/6 inhibitor therapy
  • Assess the role of current and emerging CDK4/6 inhibitory therapies in the treatment of metastatic breast cancer
  • Evaluate clinical trial data that may change standards of care for patients with metastatic breast cancer
  • Discuss strategies to optimize management of potential adverse events associated with different CDK4/6 inhibitory therapies in the management of metastatic breast cancer
  • Identify which patients may benefit from these agents and the importance of thorough tumor characterization

Faculty, Staff, and Planners' Disclosures

Chair

Joyce O’Shaughnessy, MD
Co-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology
The US Oncology Network
Dallas, TX

Disclosure: Consultant: Arno Therapeutics, AstraZeneca, Celgene, Corcept Therapeutics, Eisai, Genentech, GSK, Lilly, J&J, Merrimack, Novartis, Pfizer, Roche, Sanofi, Takeda, Medfusion

Faculty

Kimberly Blackwell, MD
Professor of Medicine
Duke University Medical Center
Durham, NC
 
 

Disclosure: Grant/Research Support: Celgene, Genentech, Pfizer, Novartis; Consultant: Advaxis, Bayer, Celgene, Coherus BioSciences, Eli Lilly, Genentech, Incyte, MacroGenics, Merck, Novartis, Pfizer, Pierian Biosciences, Puma Biotechnology, Roche, Sandoz

Sara Hurvitz, MD
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica–UCLA Outpatient Hematology/Oncology Practice
Associate Professor of Medicine, Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Santa Monica, CA

Disclosure: Grant/Research Support: Amgen, Bayer, Boehringer Ingelheim, Genentech, GSK, Pfizer, Roche, BioMarin, Merrimack, OBI Pharma, Puma Biotechnology, Dignitana, Medivation, Lilly, Novartis; Travel: Lilly, Novartis, OBI Pharma

Hope Rugo, MD
Professor of Medicine
Director of Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Disclosure: Grant/ Research Support: GSK, Genentech/Roche, Merck, Novartis, Plexxikon, Eisai, OBI Pharma, Amgen, Pfizer, MacroGenics, Lilly; Speaker’s Bureau: Genomic Health

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
Filter By